Biomechanistic and microarray analyses of preeclampsia markers, genes, and an immunologic presentation subtype may further help to identify whether copeptin is decreased in distinct molecular subsets of women with preeclampsia and/or depression [68–70]. Here, AVP is linked to depressive symptom measurement.